RT Journal Article SR Electronic T1 Urinary metabolite profiling identifies biomarkers for risk of progression of diabetic nephropathy in 2,670 individuals with type 1 diabetes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.21.20215921 DO 10.1101/2020.10.21.20215921 A1 Mutter, Stefan A1 Valo, Erkka A1 Aittomäki, Viljami A1 Nybo, Kristian A1 Raivonen, Lassi A1 Thorn, Lena M A1 Forsblom, Carol A1 Sandholm, Niina A1 Würtz, Peter A1 Groop, Per-Henrik YR 2020 UL http://medrxiv.org/content/early/2020/10/25/2020.10.21.20215921.abstract AB Aims This study examines associations between 51 urinary metabolites and risk of progression of diabetic nephropathy in individuals with type 1 diabetes by employing an automated nuclear magnetic resonance (NMR) metabolomics technique suitable for large-scale urine sample collections.Methods For 2,670 individuals with type 1 diabetes from the FinnDiane Study, we collected 24-hour urine samples and measured metabolite concentrations by NMR. Individuals were followed for 9.0 ± 5.0 years until their first sign of progression of diabetic nephropathy, end-stage kidney disease or study end. Cox regression analyses were performed on the entire study population (overall progression), on 1,999 individuals with normoalbuminuria and 347 individuals with macroalbuminuria at baseline.Results Seven urinary metabolites were associated with overall progression after adjustment for baseline albuminuria and chronic kidney disease stage (p < 8 × 10-4): Leucine (hazard ratio 1.47, 95% confidence interval [1.30, 1.66] per 1-SD creatinine-scaled metabolite concentration), valine (1.38 [1.22, 1.56]), isoleucine (1.33 [1.18, 1.50]), pseudouridine (1.25 [1.11, 1.42]), threonine (1.27 [1.11, 1.46]) and citrate (0.84 [0.75, 0.93]). 2-hydroxyisobutyrate was associated with overall (1.30 [1.16, 1.45]) and also progression from normoalbuminuria (1.56 [1.25, 1.95]). Six amino acids and pyroglutamate were associated with progression from macroalbuminuria.Conclusions Branched-amino acids and other urinary metabolites were associated with the progression of diabetic nephropathy on top of baseline albuminuria and chronic kidney disease. We found differences in associations for overall progression and progression from normo- and macroalbuminuria. These novel biomarker discoveries illustrate the utility of analysing urinary metabolites in entire population cohorts.Significance Statement Individuals with type 1 diabetes are vulnerable to diabetic nephropathy and would benefit from earlier detection of disease progression. Urinary metabolites as a direct read-out of kidney function are potential progression markers. However, analytical tools to quantify a broad panel of urinary metabolites at large scale and low cost are lacking. Recent developments in nuclear magnetic resonance address this need. This study in 2,670 individuals with type 1 diabetes identified ten urinary metabolites associated with progression of diabetic nephropathy. Importantly, different albuminuria categories had different urinary profiles: 2-hydroxyisobutyrate was associated with progression from normoalbuminuria and branched-chain amino acids with progression from macroalbuminuria. These results provide new potential biomarkers and highlight the potential of analysing urinary metabolites on a larger scale.Competing Interest StatementVA, KN, LR and PW are shareholders and/or employees of Nightingale Health, Ltd, a company offering nuclear magnetic resonance-based biomarker profiling for urine and blood samples. P-HG has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestle, Novartis, Novo Nordisk and Sanofi; and has received lecture fees from Astellas, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, Merck Sharp & Dohme, Mundiopharma, Novartis, Novo Nordisk, PeerVoice and Sanofi. Funding StatementFolkhalsan Research Foundation, Wilhelm and Else Stockmann Foundation, Liv och Halsa Society, Helsinki University Hospital Research Funds (TYH2018207), Novo Nordisk Foundation (NNF OC0013659), Sigrid Juselius Foundation, and Academy of Finland (299200, and 316664) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of the Helsinki and Uusimaa Hospital District and conducted in accordance with the Helsinki Declaration.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to patient privacy and consent, individual level data is not available for this study. The supplementary tables contain aggregated results per study group.